title: A comparison of aztreonam and two regimens of gentamicin in a rabbit model of intra-amniotic infection and sepsis.
abstract: OBJECTIVE
  To compare aztreonam in a standard dose with two gentamicin doses in the early treatment of experimental intra-amniotic infection in rabbits induced by intracervical inoculation with Escherichia coli.
  
  
  METHODS
  Timed pregnant rabbits on day 21 (70% of gestation) were inoculated intracervically with 10(4)-10(5) colony-forming units of E coli. After inoculation, the animals were treated with one of three regimens: 1) aztreonam at 90 mg/kg/day ("standard" dose in humans), 2) gentamicin at 4.5 mg/kg/day ("standard" dose in humans), or 3) higher-dose gentamicin at 6.0 mg/kg/day, each given in three divided doses daily. Outcomes included fever, delivery, and presence of a live fetus. At necropsy, cultures were taken from endometrium, amniotic fluid, and blood. Data were analyzed by Fisher exact test because the expected cell size was fewer than five.
  
  
  RESULTS
  Compared with rabbits treated with aztreonam, those treated with gentamicin 4.5 mg/kg/day delivered significantly more often (P = .002), had more positive cultures (P < .001), and had significantly fewer live fetuses (P < .001). Compared with rabbits treated with gentamicin 6.0 mg/kg/day, those treated with gentamicin 4.5 mg/kg/day delivered more often (P = .003), had fewer live fetuses (P = .02), and had more positive cultures (P = .02). There were no significant differences between the aztreonam and gentamicin 6.0 mg/kg/day groups.
  
  
  CONCLUSIONS
  This study demonstrates in an animal model that aztreonam and gentamicin at 6.0 mg/kg/day are more effective than gentamicin at 4.5 mg/kg/day (a dose that is widely used empirically in humans) in the early treatment of experimental intra-amniotic infection in rabbits. Aztreonam was as effective as gentamicin at 6.0 mg/kg/day. In this rabbit model, in which intra-amniotic infection is accompanied by maternal sepsis, 4.5 mg/kg/day of gentamicin was not adequate for the treatment of severe maternal infection.
authors.affiliation: Department of Obstetrics and Gynecology, Kaiser Permanente and Saint Joseph Hospital, Denver, Colorado, USA.
authors.forename: R S
authors.initials: RS
authors.lastname: McDuffie
authors.forename: L N
authors.initials: LN
authors.lastname: Heddleston
authors.forename: S J
authors.initials: SJ
authors.lastname: Blanton
authors.forename: R S
authors.initials: RS
authors.lastname: Gibbs
mesh_terms: D000650:Amnion / Q000382:microbiology*; D000653:Amniotic Fluid / Q000382:microbiology*; D000818:Animals; D001398:Aztreonam / Q000008:administration & dosage / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004717:Endometrium / Q000382:microbiology; D004927:Escherichia coli Infections / Q000188:drug therapy*; D005260:Female; D005839:Gentamicins / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D011817:Rabbits
chemical_list: D005839:Gentamicins; D001398:Aztreonam